Table 3.
Patient no. | EBER | CD3 | CD5 | CD10 | CD20 | CD138 | BCL‐6 | MUM1 | Bcl‐2 | Ki‐67 labeling (%) | Immunophenotype |
---|---|---|---|---|---|---|---|---|---|---|---|
1 | – | – | – | – | + | – | – | + | + | 50 | Non‐GCB |
2 | – | – | – | – | + | – | – | + | – | 85 | Non‐GCB |
3 | + | – | – | – | + | – | – | + | + | 75 | Non‐GCB |
4 | – | – | – | – | + | – | – | + | – | 60 | Non‐GCB |
5 | – | – | – | – | + | – | + | + | + | 90 | Non‐GCB |
6 | – | – | – | + | + | – | + | – | + | 80 | GCB |
7 | + | – | – | – | + | – | + | + | + | 70 | Non‐GCB |
8 | – | – | – | – | + | – | – | + | + | 60 | Non‐GCB |
9 | – | – | – | – | + | – | – | + | + | 80 | Non‐GCB |
10 | – | – | – | – | + | – | + | + | + | 80 | Non‐GCB |
11 | – | – | – | – | + | – | – | + | – | 90 | Non‐GCB |
12 | – | – | – | + | + | – | + | + | – | 50 | GCB |
13 | – | – | – | + | + | – | + | – | + | 55 | GCB |
14 | – | – | – | – | + | – | – | + | – | 90 | Non‐GCB |
15 | – | – | – | – | + | – | – | + | + | 90 | Non‐GCB |
16 | – | – | – | + | + | – | + | – | – | 50 | GCB |
17 | – | – | – | – | + | – | + | + | – | 65 | Non‐GCB |
18 | – | – | – | – | + | – | + | + | – | 80 | Non‐GCB |
19 | – | – | – | – | + | – | – | + | – | 90 | Non‐GCB |
20 | – | – | – | – | + | – | + | + | + | 40 | Non‐GCB |
21 | – | – | – | – | + | – | – | + | + | 60 | Non‐GCB |
EBER, Epstein–Barr virus‐encoded small RNA; GCB, germinal center B‐cell.